| Description |
1 online resource (289 pages) |
| Contents |
Acknowledgements; Contents; Contributors; Part I: Introduction; Chapter 1: Introducing Decision Making in a World of Comparative Effectiveness Research; Reference; Chapter 2: Perspectives of Comparative Effectiveness Research from the World of Decision Making; 2.1 Initial Thoughts on the Evolving Conception of CER; 2.2 A Survey of Key Themes Covered in this Book; 2.2.1 How Are Demands for Evidence of Comparative Effectiveness Changing? What Strategies Are Available to Manufacturers?; 2.2.2 How Have Methods for Conducting CER Changed? What Is the Emerging Picture? |
|
2.2.3 What Has Been the Impact of CER on Public Payers in the United States (US) Compared with Other National Health Systems? How Is this Changing?2.2.4 What Are Current Constraints or Barriers to the Use of CER, and How Could this Change?; 2.3 Closing Thoughts; References; Part II: The Future of Comparative Effectiveness Research for Evidence Developers: Perspectives from Pharmaceutical Decision Makers; Chapter 3: Perspectives on the Use of Comparative Effectiveness Research by Life Sciences Executives: An Interview with Mike Bonney; References |
|
Chapter 4: Perspectives on the Use of Comparative Effectiveness Research by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science CompanyReference; Chapter 5: Comparative Effectiveness Research: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies; 5.1 Introduction; 5.2 What Is CER in the Pharmaceutical Context?; 5.3 What Are the Current Efforts Toward Using CER?; 5.4 What Are the Current Challenges and Barriers for CER Research?; 5.4.1 Challenges and Costs Associated with Designing the Study |
|
5.4.1.1 Randomized Clinical Trials vs. Observational Studies5.4.1.2 Determining Comparators; 5.4.1.3 Choice of Outcomes; 5.4.1.4 Funding and Perceived Bias; 5.4.2 Challenges Stemming from the Potential Uses of CER; 5.4.2.1 Multiple Uses Each with Varying Purposes; 5.4.2.2 Challenges Associated with Dissemination of CER; 5.4.3 Barriers from Current Reimbursement Structures and Pricing Strategies in Pharmaceuticals; 5.4.4 Challenges Associated with Individual Response to Treatments; 5.4.5 Lack of Societal Consensus Regarding the Measure of Value and Other Ethical Considerations |
|
5.5 What Can Reasonably Be Done in the Near Future in Terms of CER?5.6 Conclusions; References; Chapter 6: Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation; 6.1 Introduction; 6.2 Pricing and Reimbursement Decisions; 6.2.1 Pricing; 6.2.2 Reimbursement; 6.3 Payer Value-Based Approaches; 6.4 Reaching Back to Impact Drug Development; 6.5 Discussion and Policy Implications; References; Chapter 7: Pricing of Pharmaceuticals: Current Trends and Outlook and the Role of Comparative Effectiveness Research; 7.1 Background |
| Summary |
In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufactures), government (both public and private payers), as well as decision makers of all levels, both in the US and globally |
| Notes |
7.2 Some Biopharmaceutical Pricing Specificities |
| Bibliography |
Includes bibliographical references at the end of each chapters |
| Notes |
Print version record |
| Subject |
Medicine.
|
|
Pharmaceutical technology.
|
|
Pharmacy management.
|
|
Statistics.
|
|
Medical economics.
|
|
Medicine
|
|
Technology, Pharmaceutical
|
|
Economics, Medical
|
|
medicines (material)
|
|
medicine (discipline)
|
|
statistics.
|
|
Medical economics
|
|
Medicine
|
|
Pharmaceutical technology
|
|
Pharmacy management
|
|
Statistics
|
| Form |
Electronic book
|
| Author |
Greenberg, Paul E
|
| ISBN |
9789811032622 |
|
9811032629 |
|
9789811032615 |
|
9811032610 |
|
